

November 25, 2014



## **Tonix Pharmaceuticals to Present at the LD Micro Investor Conference**

NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the LD Micro Main Event VII Conference in Los Angeles, CA. Seth Lederman, M.D., Tonix's chief executive officer, will deliver a corporate overview on Tuesday, December 2, 2014 at 8:00 a.m. PT (11:00 a.m. ET).

The presentation will be webcast live and may be accessed in the Events tab of the Investor Relations page of Tonix's website at [www.tonixpharma.com](http://www.tonixpharma.com). The webcast will be archived for 60 days.

Tonix will also be available for one-on-one meetings at the conference.

### **About Tonix Pharmaceuticals Holding Corp.**

Tonix Pharmaceuticals is a clinical-stage company developing first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's lead candidate, TNX-102 SL, is intended to be a first-line treatment for fibromyalgia and for PTSD. A Phase 2b trial of TNX-102 SL in fibromyalgia (BESTFIT) has been completed with an optimal therapeutic dose identified, and Tonix is preparing to initiate a Phase 3 program to support registration. A Phase 2 trial of TNX-102 SL in PTSD (AtEase) is expected to begin in the fourth quarter of 2014. TNX-201 is in development for episodic tension-type headache and is currently being evaluated in a Phase 1 trial. To learn more, please visit [www.tonixpharma.com](http://www.tonixpharma.com).

### **Forward-Looking Statements**

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an*

*obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 28, 2014 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

CONTACT: Tonix Pharmaceuticals Holding Corp.  
Leland Gershell  
Chief Financial Officer  
(212) 980-9155 x104  
leland.gershell@tonixpharma.com

Investor Relations:  
Martini Communications, LLC  
Amy Martini  
amartini@martinicomcommunications.com

Public Relations:  
Dian Griesel Int'l.  
Susan Forman / Laura Radocaj  
(212) 825-3210  
sforman@dgicomm.com  
lradocaj@dgicomm.com

Source: Tonix Pharmaceuticals Holding Corp.